186 related articles for article (PubMed ID: 24966994)
1. RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines.
Li XX; Zheng HT; Peng JJ; Huang LY; Shi DB; Liang L; Cai SJ
Int J Clin Exp Pathol; 2014; 7(5):2729-36. PubMed ID: 24966994
[TBL] [Abstract][Full Text] [Related]
2. Clinical determinants of response to irinotecan-based therapy derived from cell line models.
Allen WL; Coyle VM; Jithesh PV; Proutski I; Stevenson L; Fenning C; Longley DB; Wilson RH; Gordon M; Lenz HJ; Johnston PG
Clin Cancer Res; 2008 Oct; 14(20):6647-55. PubMed ID: 18927307
[TBL] [Abstract][Full Text] [Related]
3. Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer.
Makondi PT; Chu CM; Wei PL; Chang YJ
PLoS One; 2017; 12(7):e0180616. PubMed ID: 28749961
[TBL] [Abstract][Full Text] [Related]
4. RNA-seq identifies determinants of oxaliplatin sensitivity in colorectal cancer cell lines.
Li XX; Peng JJ; Liang L; Huang LY; Li DW; Shi DB; Zheng HT; Cai SJ
Int J Clin Exp Pathol; 2014; 7(7):3763-70. PubMed ID: 25120752
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan.
Meisenberg C; Ashour ME; El-Shafie L; Liao C; Hodgson A; Pilborough A; Khurram SA; Downs JA; Ward SE; El-Khamisy SF
Nucleic Acids Res; 2017 Feb; 45(3):1159-1176. PubMed ID: 28180300
[TBL] [Abstract][Full Text] [Related]
6. UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients.
Cacciola NA; Calabrese C; Malapelle U; Pellino G; De Stefano A; Sepe R; Sgariglia R; Quintavalle C; Federico A; Bianco A; Uchimura Bastos A; Milone M; Bellevicine C; Milone F; Carlomagno C; Selvaggi F; Troncone G; Fusco A; Pallante P
Mol Carcinog; 2016 May; 55(5):793-807. PubMed ID: 25917796
[TBL] [Abstract][Full Text] [Related]
7. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
To KK; Leung WW; Ng SS
Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386
[TBL] [Abstract][Full Text] [Related]
8. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
Dopeso H; Mateo-Lozano S; Elez E; Landolfi S; Ramos Pascual FJ; Hernández-Losa J; Mazzolini R; Rodrigues P; Bazzocco S; Carreras MJ; Espín E; Armengol M; Wilson AJ; Mariadason JM; Ramon Y Cajal S; Tabernero J; Schwartz S; Arango D
Clin Cancer Res; 2010 Apr; 16(8):2375-82. PubMed ID: 20371676
[TBL] [Abstract][Full Text] [Related]
9. Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo.
Wood JP; Smith AJ; Bowman KJ; Thomas AL; Jones GD
Cancer Med; 2015 Sep; 4(9):1309-21. PubMed ID: 26108357
[TBL] [Abstract][Full Text] [Related]
10. Identification of candidate genes and miRNAs for sensitizing resistant colorectal cancer cells to oxaliplatin and irinotecan.
Poorebrahim M; Sadeghi S; Ghanbarian M; Kalhor H; Mehrtash A; Teimoori-Toolabi L
Cancer Chemother Pharmacol; 2020 Jan; 85(1):153-171. PubMed ID: 31781855
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.
Allen WL; Turkington RC; Stevenson L; Carson G; Coyle VM; Hector S; Dunne P; Van Schaeybroeck S; Longley DB; Johnston PG
Mol Cancer Ther; 2012 Aug; 11(8):1724-34. PubMed ID: 22665525
[TBL] [Abstract][Full Text] [Related]
12. The identification of CRNDE, H19, UCA1 and HOTAIR as the key lncRNAs involved in oxaliplatin or irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis.
Sun F; Liang W; Qian J
Mol Med Rep; 2019 Oct; 20(4):3583-3596. PubMed ID: 31432188
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab in the treatment of patients with colorectal cancer.
Garrett CR; Eng C
Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
[TBL] [Abstract][Full Text] [Related]
14. Two novel camptothecin derivatives inhibit colorectal cancer proliferation via induction of cell cycle arrest and apoptosis in vitro and in vivo.
Du H; Huang Y; Hou X; Quan X; Jiang J; Wei X; Liu Y; Li H; Wang P; Zhan M; Ai X; Lu L; Yuan S; Sun L
Eur J Pharm Sci; 2018 Oct; 123():546-559. PubMed ID: 30118848
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.
Crea F; Giovannetti E; Cortesi F; Mey V; Nannizzi S; Gallegos Ruiz MI; Ricciardi S; Del Tacca M; Peters GJ; Danesi R
Mol Cancer Ther; 2009 Jul; 8(7):1964-73. PubMed ID: 19531575
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.
Ikeguchi M; Arai Y; Maeta Y; Ashida K; Katano K; Wakatsuki T
Surg Today; 2011 Sep; 41(9):1196-9. PubMed ID: 21874414
[TBL] [Abstract][Full Text] [Related]
17. [[Irinotecan--experience with second-line treatment in advanced colorectal cancer] ].
Kristó K; Izsó J; Balatoni G; Lohinszky J; Farczádi E; Szántó J; Kofi AP; Pintér T
Orv Hetil; 2000 Aug; 141(33):1817-20. PubMed ID: 10979311
[TBL] [Abstract][Full Text] [Related]
18. Gene signatures of drug resistance predict patient survival in colorectal cancer.
Zheng Y; Zhou J; Tong Y
Pharmacogenomics J; 2015 Apr; 15(2):135-43. PubMed ID: 25179828
[TBL] [Abstract][Full Text] [Related]
19. CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer.
Hagiwara T; Sugimoto K; Momose H; Irie T; Honjo K; Okazawa YU; Kawai M; Kawano S; Munakata S; Takahashi M; Kojima Y; Serizawa N; Nagahara A; Hoffman RM; Brock MV; Sakamoto K
Anticancer Res; 2022 Feb; 42(2):697-707. PubMed ID: 35093868
[TBL] [Abstract][Full Text] [Related]
20. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.
Raynal C; Pascussi JM; Leguelinel G; Breuker C; Kantar J; Lallemant B; Poujol S; Bonnans C; Joubert D; Hollande F; Lumbroso S; Brouillet JP; Evrard A
Mol Cancer; 2010 Mar; 9():46. PubMed ID: 20196838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]